| Literature DB >> 33633954 |
Rui Liu1, Gui-Ling Mo2, Yuan-Zong Song1.
Abstract
Pearson syndrome (PS), also known as Pearson marrow-pancreas syndrome, is a rare, multi-systemic disorder caused by large-scale deletion of mitochondrial DNA (mtDNA) ranging from 2.3 kb to 9 kb, with 4,977 bp in length as the most common variant. This paper reported a novel mtDNA deletion of 4,734 bp in size, spanning from nucleotide 11,220 to 15,953. The infant suffered from chronic hepatomegaly, liver dysfunction, anemia and lactic acidosis over 1 year. Evidences of any infections were negative. Bone marrow aspiration and whole exome sequencing covering nearly 20,000 nucleus genes were performed when aged 3.3 and 6 months, respectively, but no genetic cause was identified. However, at his age 13 months, multiplex ligation-dependent probe amplification assay of the mtDNA in the patient detected a large deletion of 4,734 bp in size spanning the mitochondrial genes MTND4, MTTH, MTTS2, MTTL2, MTND5, MTND6, MTTE, MTCYB and MTTT which were functionally crucial for the intact oxidative phosphorylation pathway and adenosine triphosphate production, and PS was thus definitely diagnosed. This large deletion was negative in his parents and elder brother. Oral ursodeoxycholic acid, fat-soluble vitamins and blood transfusions were administrated, his clinical and laboratory presentations remained stable so far, but the long-term prognosis needed to be followed up. These findings enriched the variant spectrum of mtDNA, and demonstrated the importance of considering mitochondrial disorder in patient with intractable anemia, liver dysfunction and lactic acidosis as well as the significance of appropriate choosing of relevant genetic tools in the etiology diagnosis of such patients. 2021 Translational Pediatrics. All rights reserved.Entities:
Keywords: Infant; Pearson syndrome (PS); case report; mitochondrial DNA (mtDNA); variant
Year: 2021 PMID: 33633954 PMCID: PMC7882279 DOI: 10.21037/tp-20-138
Source DB: PubMed Journal: Transl Pediatr ISSN: 2224-4336
Laboratory indices over time in the patient
| Indices (reference range) | Ages | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 D | 4 D | 1 M 3 D | 1 M 27 D | 2 M 6 D | 2 M 11 D | 8 M 23 D | 10 M 24 D | 13 M | |
| ALT (5–40 U/L) | – | 24 | – | – | 42 | – | 106 | 131 | 107 |
| AST (8–40 U/L) | – | 60 | 119 | 107 | 120 | 92 | 112 | 105 | 180 |
| GGT (7–50 U/L) | – | 157 | 759 | 248 | – | 94 | 251 | 319 | 352 |
| TBA (0–10 μmol/L) | 91.0 | – | 33.7 | 282.0 | – | 267.9 | 13.4 | 19.9 | 98.1 |
| TBIL (2–17 μmol/L) | 216.9 | 260.7 | 70.6 | 232.5 | 163.9 | 185.0 | – | 9.6 | 17.7 |
| DBIL (0–7 μmol/L) | – | 22.3 | 24.2 | 165.7 | 120.6 | 123.3 | – | 3.7 | 8.8 |
| IBIL (2–13.7 μmol/L) | – | 238.4 | 46.4 | 66.8 | – | 62.6 | – | 5.9 | 8.9 |
| RBC [(4–4.5) ×1012/L] | – | 3.35 | 2.43 | 2.59 | 2.26 | 3.57 | 2.80 | 2.72 | 2.88 |
| HGB (105–145 g/L) | 91 | 122 | 75 | 79 | 66 | 104 | 108 | 87 | 108 |
| Lactate (0.9–1.7 mmol/L) | – | 7.5 | 10.2 | 19.2 | 18.2 | 8.5 | 3.2 | – | 6.5 |
D, day; M, month; ALT, alanine transaminase; AST, aspartate transaminase; TBA, total bile acids; GGT, gamma-glutamyl transpeptidase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; RBC, red blood cells; HGB, hemoglobin.
Figure 1MLPA assay results of the patient. The horizontal axis represented the probe positions, while the vertical, the fluorescence signal ratio of subject sample/normal control which was represented as mean ± SD in this figure. On the top were the probe labels. The red and the blue curves represented the normal upper and lower limits of the ratios, respectively. The green boxes indicated the reliability of the experiments. The 9 genes MTND4, MTTH, MTTS2, MTTL2, MTND5, MTND6, MTTE, MTCYB and MTTT (dots in red on the right) displayed ratios ranging from 0.25 to 0.75, indicating a large deletion. The remaining 23 mtDNA genes (dots in black) exhibited normal ratios. MLPA, multiplex ligation-dependent probe amplification; SD, standard deviation.
Figure 2Timeline of the patient.